Figure 3. A significant decrease (p<0.05) in myocardial ¹¹C-radiotracer exposure (area under the time–activity curve (AUC)) with phase I compared with pre-phase I doses of DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide) demonstrated myocardial saturation. However, a significant increase in tumour exposure was seen, signifying a lack of tumour saturation with the 3-h infusion of DACA.